CPV 3360
Pharmaceutical products
26 active tenders tagged under this CPV division — sort, filter, and drill in via the master tenders page.
Working Collaboratively Opportunity – Supporting School Access to Adrenaline Auto-Injectors (AAIs)
Department for Education
Keeping children and young people with allergies safe while in school is a key priority for the Government. Section 34 of the Children’s Wellbeing and Schools Act 2026 (www.legislation.gov.uk/ukpga/2026/21/section/34/enacted) places new allergy safety duties on schools. We have published new statutory guidance on Allergy safety in schools (www.gov.uk/government/publications/allergy-safety-in-schools). Currently under the Human Medicines (Amendment) Regulations 2017, schools in England are permitted to purchase “spare” adrenaline auto-injectors (AAIs) without a prescription for emergency use in cases of anaphylaxis. The Government intends to require all schools to stock “spare” AAIs. Further education (FE) colleges and other post‑16 institutions are not included in this exemption. Any extension would require regulatory change, which has not yet been implemented. Suppliers should therefore continue to operate in line with the current legal framework. This early engagement supports the Department for Education’s (DfE) preparatory work ahead of new statutory guidance, with the aim of ensuring schools can access “spare” adrenaline auto-injectors (AAIs) quickly, reliably and affordably to support pupil safety. The Department is therefore initiating early market engagement with organisations that supply AAIs, including manufacturers, distributors, wholesalers and other authorised suppliers, to better understand the current market landscape and the options available to support schools in accessing “spare” AAIs. This engagement will inform consideration of a potential working sponsorship approach, through which the provider market may develop voluntary commercial offers directly to schools in return for a rights package. The intention is to support improved affordability, simplify access, and enhance reliability of supply, while maintaining schools’ independence in purchasing decisions. To inform this approach, the Department is seeking insight into existing routes to market
Posebno skupi lijekovi (koji nisu obuhvaćeni ZN) - 1. dio
OPĆA BOLNICA ZADAR, Zadar
Nabava lijekova
DOM ZDRAVLJA SPLITSKO-DALMATINSKE ŽUPANIJE, Split
NHS National Framework for Lenvatinib
NHS England
Project title: NHS National Framework for Lenvatinib Offer reference number: CM/TNS/26/5751 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to a maximum of 24 months. CM/TNS/26/5751 Lenvatinib Lot 1 CESW: 01/06/2027 to 31/01/2029 (20 months) Lot 2 NWLN: 01/06/2027 to 30/09/2028 (16 months) Lot 3 LSNE: 01/06/2027 to 31/05/2028 (12 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England
Lijek denosumab - iznimna žurnost (u vrijednosti od 7.779,60 EUR bez PDV-a)
Klinički bolnički centar Rijeka, Rijeka
Lijekovi -inovativna onkološka terapija
ZU KANTONALNA BOLNICA "DR. IRFAN LJUBIJANKIĆ" BIHAĆ
Ostali lijekovi (koji nisu obuhvaćeni ZN) - 2. dio
OPĆA BOLNICA ZADAR, Zadar
Lijekovi alergeni za prick test i alergijsku imunoterapiju - iznimna žurnost
Klinički bolnički centar Rijeka, Rijeka
Lijekovi relugoliks, bisoprolol - iznimna žurnost (u vrijednosti od 2.333,01 EUR bez PDV-a)
Klinički bolnički centar Rijeka, Rijeka
Lijekovi digoksin, klotrimazol, aminofilin, montelukast, tikagrelor - iznimna žurnost (u vrijednosti od 3.656,45 EUR bez PDV-a)
Klinički bolnički centar Rijeka, Rijeka
Lijekovi sildenafil, eritropoetin theta, doksorubicin, izotretinoin, klindamicin, pioglitazon + glimepirid, dinoproston, acetilcistein, solifenacin, prokarbazin, mikofenolat-natrij, eptifibatid, tiotepa, tikagrelor - iznimna žurnost
Klinički bolnički centar Rijeka, Rijeka
NHS National Framework for the supply and treatment of Blood Disorders
NHS England
Project Title: NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A and B - January 2028 Offer reference number: CM/PHS/26/5749 Period of framework: 1 January 2028 to 31 December 2029 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England. The commencement of procurement and award of any subsequent contract will be subject to budgetary approval.
Lijekovi raznih skupina po ATC kodu za potrebe KCUS-a I/14/2026 (dio skupine A, B, C, D, G i H)
UNIVERZITETSKI KLINIČKI CENTAR SARAJEVO - UKCS
Lijekovi na listama HZZO-a koji imaju generičke paralele i Ostali lijekovi
KLINIKA ZA INFEKTIVNE BOLESTI DR. FRAN MIHALJEVIĆ, Grad Zagreb
Lijekovi fingolimod, oksazepam, klotrimazol, salmeterol + flutikazon, tiotropij bromid, mesalazin, klonidin - iznimna žurnost (u vrijednosti od 20.774,30 EUR bez PDV-a)
Klinički bolnički centar Rijeka, Rijeka
NHS National Framework for Abatacept Injection
NHS England
Project title: NHS National Framework for Abatacept Injection Offer reference number: CM/TNS/26/5764 Suppliers who are planning to introduce the molecule(s) detailed in the framework title, or who have any questions regarding a potential upcoming procurement exercise, are invited to contact the MPSC New Market Developments Team. Please email barbara.sly@nhs.net, marie.graney1@nhs.net, and katie.noonan@nhs.net
NHS National Framework for Cladribine tablets
NHS England
Project title: NHS National Framework for Cladribine tablets Offer reference number: CM/TNS/26/5765 Suppliers who are planning to introduce the molecule(s) detailed in the framework title, or who have any questions regarding a potential upcoming procurement exercise, are invited to contact the MPSC New Market Developments Team. Please email barbara.sly@nhs.net, marie.graney1@nhs.net, and katie.noonan@nhs.net
NHS National Framework for Trastuzumab Subcutaneous Injection
NHS England
Project title: NHS National Framework for Trastuzumab Subcutaneous Injection Offer reference number: CM/TNS/26/5762 Suppliers who are planning to introduce the molecule(s) detailed in the framework title, or who have any questions regarding a potential upcoming procurement exercise, are invited to contact the MPSC New Market Developments Team. Please email barbara.sly@nhs.net, marie.graney1@nhs.net, and katie.noonan@nhs.net
NHS National Framework for Vedolizumab Injection
NHS England
Project title: NHS National Framework for Vedolizumab Injection Offer reference number: CM/TNS/26/5763 Suppliers who are planning to introduce the molecule(s) detailed in the framework title, or who have any questions regarding a potential upcoming procurement exercise, are invited to contact the MPSC New Market Developments Team. Please email barbara.sly@nhs.net, marie.graney1@nhs.net, and katie.noonan@nhs.net
NHS National Framework for Ivacaftor
NHS England
Project title: NHS National Framework for Ivacaftor Offer reference number: CM/TNS/26/5766 Suppliers who are planning to introduce the molecule(s) detailed in the framework title, or who have any questions regarding a potential upcoming procurement exercise, are invited to contact the MPSC New Market Developments Team. Please email barbara.sly@nhs.net, marie.graney1@nhs.net, and katie.noonan@nhs.net
Generic Drugs - Tablets and Capsules 2
NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)
This is a contract for the provision of Tablets and Capsules Drugs
NHS National Framework Tenofovir alafenamide/Emtricitabine 200/10mg & 200/25mg
NHS England
Project title: NHS National Framework Tenofovir alafenamide/Emtricitabine 200/10mg & 200/25mg Offer reference number: CM/TNS/26/5744 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to a maximum of 24 months. CM/TNS/26/5744 Tenofovir alafenamide/Emtricitabine 200/10mg & 200/25mg Lot 1 LNW 1 February 2027 to 31 October 2028 (21 months) Lot 2 DNE & SOFE 1 February 2027 to 31 October 2028 (21 months) Lot 3 DNW & MAE 1 February 2027 to 31 October 2028 (21 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England
Лекови ван листе лекова -Блинатумомаб
ИНСТИТУТ ЗА ЗДРАВСТВЕНУ ЗАШТИТУ МАЈКЕ И ДЕТЕТА СРБИЈЕ "ДР ВУКАН ЧУПИЋ", БЕОГРАД, ПИБ: 100136676
Lijekovi feksofenadin, buprenorfin, kalij-klorid - iznimna žurnost (u vrijednosti od 1.524,84 EUR bez PDV-a)
Klinički bolnički centar Rijeka, Rijeka